Accuracy Performance Verification of the INVOS™ PM7100 System in Adults

Medtronic

Status: Completed

Conditions: Oxygen Saturation

Treatments: Device: Observational

Study type: Observational

Funder types: Industry

Identifiers

NCT06581835

MDT23038INSENS

Details and patient eligibility

About

Prospective, observational, post-market, verification study to ensure compliance to the ISO 80601-2-85:2021 standard

Full description

The purpose of this study is to provide data for verification of the INVOS™ PM7100 System paired with the Adult Sensor (PMSENS71-A). Medtronic evaluates the performance and/or feasibility of non-invasive optical devices over a clinically relevant range of arterial saturations. This study evaluates rSO2 accuracy of tissue oximetry equipment compared directly to the actual saturation of arterial and jugular blood samples (SaO2) and (SjvO2) and the composite of the two (SavO2) as measured by co-oximetry.

Enrollment: 42 patients

Sex: All

Ages: 18 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Subjects between the ages of 18 to 50 years
2. Completion of a health screening for medical history by a licensed physician, nurse practitioner, or physician assistant
3. Minimum weight 40kg
4. BMI within range 18.0 - 29.9

Exclusion criteria

1. Prior or known allergies to lidocaine (or similar pharmacologic agents, e.g., Novocain) [self-reported]
2. Prior known severe allergies to medical grade adhesive/tape (Band-Aid) [self-reported]
3. Subjects taking medication(s) beyond birth control may be excluded from participating at the PI discretion [self-reported]
4. Any interventional study within 30 days that, in the opinion of the PI, electrocardiogram (ECG) may interfere with study participation (i.e., drug, biologic)
5. Negative Allen's test for radial and ulnar patency
6. Has made a whole blood donation or has had at least 450 ml of blood drawn within 8 weeks prior to the study procedure [self-reported]
7. Is pregnant
8. Has anemia as measured by co-oximetry [values specific for sex]
9. Has a history of sickle cell trait or thalassemia [self-reported]
10. Has an abnormal hemoglobin electrophoresis test [lab measurement]
11. Has a positive urine cotinine test or urine drug screen or oral ethanol test [Point of Care (POC) testing]
12. Has a room air saturation less than 95% by pulse oximetry [measurement by PI or delegate]
13. Has a clinically significant abnormal ECG [assessment by PI or delegate]
14. Has a clinically significant abnormal pulmonary function test via spirometry [assessment by PI or delegate]
15. Has a COHb greater than 3%, or MetHb greater than 2% [measured by venous blood sample co-oximetry]

Trial design

42 participants in 1 patient group

Observational

Description:

Healthy, non-smoking volunteers ages 18-50 years who meet inclusion criteria

Treatment:

Device: Observational